News

People with cystic fibrosis (CF) are more frequently infected with oral Candida fungus and carry a higher number of fungi than healthy individuals, a study has found. All fungal species identified in the study’s CF patients were susceptible to currently available anti-fungal medications. The study, “Oral…

The government of  Northern Ireland reached a deal with Vertex Pharmaceuticals to make Kaftrio (ivacaftor/tezacaftor/elexacaftor) available for cystic fibrosis (CF) patients, once the medication receives its European license. The agreement follows similar ones that the company made recently with England and Wales.

A new study will assess the real-world effects of Vertex Pharmaceutical‘s Trikafta, a triple combo of elexacaftor, tezacaftor, and ivacaftor approved by the U.S. Food and Drug Administration (FDA) for treating up to 90% of all people with cystic fibrosis (CF). The $3.63 million study (3.06…

Researchers have developed the first thread-based flexible patch that can be sewn into clothing to monitor — in real time — several molecules in sweat, including chloride ions, which are dysregulated in cystic fibrosis (CF) patients. The study describing that finding, “Thread-based multiplexed sensor patch for…

This year’s Cystic Fibrosis Foundation (CFF) Impact Grants, which provide up to $10,000 in funding, will support and empower the cystic fibrosis (CF) community through four new virtual programs focused on engaging and connecting patients. Now in its fifth year, the program helps individuals and organizations whose projects…

After raising more than $268,828 ($360,000 Canadian dollars) since 2017 for Cystic Fibrosis Canada, thyssenkrupp Elevator Canada received the nonprofit’s 2019 National Champion Award. The award recognizes companies, service groups, and other entities that have a presence in at least three regions of Canada and have provided exceptional…

AzurRx BioPharma has launched a Phase 2b clinical trial investigating its MS1819 as a potential treatment for exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). The first patient has now been screened in the OPTION 2 trial (NCT04375878), which has opened at three…

The Welsh government and Vertex Pharmaceuticals have reached an agreement that will allow access to the company’s Kaftrio (ivacaftor/tezacaftor/elexacaftor) for cystic fibrosis (CF) patients as soon as the medication is approved in Europe. Kaftrio is a triple combination therapy for the treatment of CF, designed to…

ContraFect has been awarded to $18.9 million by the nonprofit investment group CARB-X to advance CF-370 as a potential treatment for Pseudomonas aeruginosa infections. These bacteria and the thick layer of biofilm they produce are a major cause of pulmonary exacerbations in cystic fibrosis (CF) patients. CARB-X, which stands for…

Levels of inflammatory markers in the lungs may help predict pulmonary exacerbations in children with cystic fibrosis (CF), a new study suggests. The study, “BAL inflammatory markers can predict pulmonary exacerbations in children with cystic fibrosis,” was published in the journal Chest. In people…